You lost weight, then the scale stopped moving for three months, and your provider just says "stay the course." Before you chase a second molecule, it helps to actually understand the tool you are asking about, not the promise someone is selling around it.
Two hormones, two doorbells
Your gut releases hormones after you eat. Two of them matter for this conversation: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are called incretins, meaning they help your body handle food and blood sugar. Think of each as a doorbell that rings a specific receptor on your cells.
Semaglutide rings one doorbell: the GLP-1 receptor [1]. Tirzepatide is engineered to ring two: it activates both the GIP receptor and the GLP-1 receptor from a single molecule [2]. That is what people mean by "dual action." It is not a stronger version of the same signal. It is a second, different signal added on top.
What GLP-1 activation does
GLP-1 receptor activity does a few well-documented things. It prompts the pancreas to release insulin in a glucose-dependent way (meaning mostly when blood sugar is elevated), slows how fast the stomach empties, and acts on appetite centers in the brain to reduce hunger [1][3]. This is the pathway DeShawn's current compounded protocol has been working. When someone loses weight early and then stalls, the underlying biology of a plateau is not a mystery: as body mass drops, the body defends its weight by lowering energy expenditure and increasing appetite drive, a well-described adaptive response [4]. A plateau is not automatically a sign the medication "stopped working"; it can reflect that biology.
What adding GIP does
Here is where the honest science gets interesting, and where you should be skeptical of anyone speaking in absolutes. GIP's role in body weight is still being worked out by researchers. In the context of tirzepatide, GIP receptor activation is thought to contribute to insulin secretion and to influence appetite and how the body handles fat, working alongside GLP-1 signaling rather than duplicating it [2][5]. The Endocrine Society and peer-reviewed reviews describe tirzepatide as a dual GIP and GLP-1 receptor agonist precisely because the second pathway is believed to add something the first does not [2][5]. What that means for any one person is exactly the kind of question an independent provider reviews against your labs and history, not a guarantee that a second pathway will break a specific stall.
Source: [1] Glucagon-like peptide-1 receptor agonists (StatPearls / NCBI Bookshelf), [2] Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist (peer-reviewed review, PMC)
Why "protect my strength" is the right instinct
DeShawn's worry about losing muscle while he leans out is not paranoia; it is good coaching. Weight loss from any method, including reduced-calorie eating, tends to include loss of lean mass alongside fat mass. Clinical guidance on obesity management emphasizes resistance training and adequate protein intake to help preserve lean tissue during weight loss [6]. That is a conversation to have with a provider who knows your training background, not a setting you toggle on a portal. An ex-athlete's frame carries more muscle to begin with, which is part of why an individualized read matters more than a template.
The numbers that actually deserve monitoring
Michael's alarming physical results are the real signal here, more than the number on the scale. Metabolic risk lives in your bloodwork: fasting glucose, HbA1c, lipids, and blood pressure. The American Diabetes Association defines prediabetes and diabetes by specific thresholds, and those thresholds are how a provider tracks whether metabolic health is trending in the right direction over time [7].
This is the difference between a vending-machine portal and genuine oversight. "Stay the course" is not a plan; a plan is baseline labs, a clear reason for any change, and follow-up bloodwork to see how your body actually responds. A provider deciding whether a switch makes sense for you is weighing your glucose numbers, your lipids, your kidney and liver markers, your history, and your goals, not just the fact that the scale is stuck.
mg/dL fasting glucose · marker = Prediabetes starts
Source: [7] American Diabetes Association Standards of Care: Diagnosis and Classification
Source: [6] Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, [7] American Diabetes Association Standards of Care: Diagnosis and Classification
Safety context you should know before you ask
Both GLP-1 and dual GIP/GLP-1 medications share a class of common side effects, mostly gastrointestinal: nausea, diarrhea, vomiting, and constipation, especially early on [2][3]. There are also labeled warnings, including a boxed warning about thyroid C-cell tumors seen in rodent studies, and cautions in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [3]. These are the reasons a licensed provider reviews your history before prescribing anything, and why a prescription is never guaranteed.
One more thing to understand plainly: compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Switching is a medical decision, not a checkout upgrade
DeShawn does not want to start over with another sketchy provider, and Michael does not want a six-week wait for a seven-minute visit. Both are reasonable. But the takeaway from the mechanism is this: a second receptor pathway is a different tool, not a guaranteed fix for a plateau. Whether moving from a single-pathway to a dual-pathway approach is appropriate for you depends on your labs, your response so far, your side-effect history, and your goals. That is a judgment an independent licensed provider makes with you, using real data.
This article is educational and is not medical advice. It cannot tell you whether to switch anything.
Where Velri fits
Velri is a technology and coordination company, not a medical provider. Velri helps coordinate the parts that make a real review possible: lab work, a visit with an independent, physician-led Provider Group licensed in your state, and, if a provider writes a prescription, fulfillment through an independent licensed pharmacy. Through the Velri clinical review process, an independent provider looks at your bloodwork and history and decides what, if anything, is appropriate for you; a prescription is never guaranteed. Coverage starts in Nevada, with more states rolling out. Velri's role is to make genuine oversight accessible, so the decision about a second pathway is made with data, not sold from a portal.
